Genomic alterations are common in metastatic castration-resistant prostate cancer (mCRPC), but limited data exist on the response to 177Lu-PSMA-617 (LuPSMA) in patients with these aberrations. We ...

In the CHAARTED trial (Chemo Hormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer), metastatic hormone-sensitive prostate cancer (mHSPC) patients with ...

PET/CT with 18F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may surpass current guideline recommendations. The aim of the present study is to ...

The incidence of androgen receptor (AR)–negative (AR−) prostate cancer, including aggressive neuroendocrine prostate cancer (NEPC), has more than doubled in the last decade, but its timely diagnosis ...

Objectives The aim of our study was to compare two methods for SUVr calculations in amyloid PET brain imaging. Methods In a continuing study, 19 patients were imaged on a GE STE 16 slice PET/CT system ...

Associations of [18 F]PI-2620 Binding with Memory and Phosphorylated Tau 217 in Cognitively Unimpaired Older Adults ...

Learning Objectives 1. To review the epidemiology, pathology, and clinical presentation of calciphylaxis. 2. To review the typical bone scan and plain x-ray findings. 3. To examine the role SPECT-CT ...

Journal of Nuclear Medicine October 2025, jnumed.124.269188; DOI: https://doi.org/10.2967/jnumed.124.269188 ...

We developed a new C-X-C chemokine receptor 4 (CXCR4)–targeting radiolabeled peptide, [68Ga]Ga/[177Lu]Lu-BL34, using a novel and potent cyclic peptide based on structure–activity relationship studies ...

Journal of Nuclear Medicine April 2026, jnumed.125.271604; DOI: https://doi.org/10.2967/jnumed.125.271604 ...

Journal of Nuclear Medicine June 2025, jnumed.125.269655; DOI: https://doi.org/10.2967/jnumed.125.269655 ...

Journal of Nuclear Medicine May 2024, jnumed.123.267321; DOI: https://doi.org/10.2967/jnumed.123.267321 ...